Page last updated: 2024-10-15

monomethylauristatin f

Description

monomethylauristatin F: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122173009
MeSH IDM0501852

Synonyms (3)

Synonym
745017-94-1
monomethylauristatin f
A865880

Pharmacokinetics

ExcerptReference
" To determine the pharmacokinetic parameters of anti-CD22-MCC-DM1 and MC-MMAF conjugates, various approaches to quantifying total and conjugated antibody were investigated."( Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Akutagawa, J; Baudys, J; Bechtel, C; Chan, P; Ebens, A; Elliott, JM; Jacobson, F; Lee, C; Nelson, C; Prabhu, S; Raab, H; Saad, O; Stephan, JP; Vandlen, R; Wong, WL; Xie, D, 2008
)
" Systemic exposure (as assessed by Cmax and AUC) of the released payload increased with increasing dose, although exposure was very low and its pharmacokinetics appeared to be formation rate limited."( Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
Duriga, N; Han, X; Kadar, E; Leal, M; Lorello, L; Lucas, J; McNally, J; Rago, B; Sapra, P; Shakey, Q; Song, W; Spriggs, F; Wentland, J; Zhang, Y, 2015
)
" We developed a mechanism-based platform model that can describe and predict the complex pharmacokinetic (PK) behavior of ADCs with protease-cleavable valine-citrulline (VC) linker linked to Monomethylmonomethyl auristatin F/E by incorporating known mechanisms of ADC disposition."( Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Carrasco-Triguero, M; Fielder, P; Gadkar, K; Leipold, DD; Lin, K; Milojic-Blair, M; Ramanujan, S; Rubinfeld, B; Saad, OM; Samineni, D; Sukumaran, S; Wang, B; Xu, K; Zhang, C, 2017
)
"A simple liquid chromatography-quadrupole-time-of-flight-mass spectrometric assay (LC-TOF-MS/MS) has been developed for the evaluation of metabolism and pharmacokinetic (PK) characteristics of monomethyl auristatin F (MMAF) in rat, which is being used as a payload for antibody-drug conjugates."( Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.
Byeon, JJ; Choi, J; Lee, BI; Park, MH; Park, Y; Shin, SH; Shin, YG, 2019
)

Bioavailability

ExcerptReference
" The PK studies showed that the bioavailability of MMAF was 0% with high clearance."( Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.
Byeon, JJ; Choi, J; Lee, BI; Park, MH; Park, Y; Shin, SH; Shin, YG, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (11.43)29.6817
2010's21 (60.00)24.3611
2020's10 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.41%)5.53%
Reviews2 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (89.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]